CHICAGO, Sept. 21 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), has received approval from the NASDAQ Listings Qualifications Staff to transfer the listing of its common stock to the NASDAQ Capital Market from the NASDAQ Global Market. The transfer is effective as of the open of the Market today. The Company continues to be listed and traded under the symbol "ADLS."
"Advanced Life Sciences currently meets all of the requirements for continued listing on the NASDAQ Capital Market," said Michael T. Flavin, Ph.D., chairman and chief executive officer. "We believe this transfer is in the best interest of all shareholders and feel the lower cost and listing requirements of the NASDAQ Capital Market better meet our needs as a public company."
The NASDAQ Capital Market includes over 550 issuers of a wide range of capitalization sizes. A NASDAQ Capital Market security satisfies all applicable qualification requirements for NASDAQ securities, and all companies listed on the NASDAQ Capital Market must meet certain financial requirements and adhere to NASDAQ's corporate governance standards.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.
|SOURCE Advanced Life Sciences Holdings, Inc.|
Copyright©2007 PR Newswire.
All rights reserved